| Robert Shotlander, | |
|
2809 Denny Ave, Pascagoula, MS 39581-5301 | |
| (228) 809-5000 | |
| Not Available |
| Full Name | Robert Shotlander |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 44 Years |
| Location | 2809 Denny Ave, Pascagoula, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144423435 | NPI | - | NPPES |
| RS00110751 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R506192 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mobile Infirmary Medical Center | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesiologists Associated Pc | 6204739519 | 361 |
News Archive
Analysts, lobbyists and journalists are still examining the announcement that three large health insurance companies would allow some of the health law's more popular consumer provisions to go forward no matter how the court decides.
A new genetic analysis, published March 19th in the open-access journal PLoS Neglected Tropical Diseases, suggests that the parasitic worm Schistosoma mekongi is more widespread than previously thought.
Pain Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) resubmission for REMOXY (controlled-release oxycodone) and has classified it as a Class 2 resubmission.
Exposure to lead during early development can alter the the gut microbiota, increasing the chances for obesity in adulthood, researchers from the University of Michigan School of Public Health have found.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."
› Verified 9 days ago
| Entity Name | Mobile Infirmary Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558364802 PECOS PAC ID: 3476456625 Enrollment ID: O20040127000970 |
News Archive
Analysts, lobbyists and journalists are still examining the announcement that three large health insurance companies would allow some of the health law's more popular consumer provisions to go forward no matter how the court decides.
A new genetic analysis, published March 19th in the open-access journal PLoS Neglected Tropical Diseases, suggests that the parasitic worm Schistosoma mekongi is more widespread than previously thought.
Pain Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) resubmission for REMOXY (controlled-release oxycodone) and has classified it as a Class 2 resubmission.
Exposure to lead during early development can alter the the gut microbiota, increasing the chances for obesity in adulthood, researchers from the University of Michigan School of Public Health have found.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."
› Verified 9 days ago
| Entity Name | Anesthesiologists Associated Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851371850 PECOS PAC ID: 6204739519 Enrollment ID: O20040202000465 |
News Archive
Analysts, lobbyists and journalists are still examining the announcement that three large health insurance companies would allow some of the health law's more popular consumer provisions to go forward no matter how the court decides.
A new genetic analysis, published March 19th in the open-access journal PLoS Neglected Tropical Diseases, suggests that the parasitic worm Schistosoma mekongi is more widespread than previously thought.
Pain Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) resubmission for REMOXY (controlled-release oxycodone) and has classified it as a Class 2 resubmission.
Exposure to lead during early development can alter the the gut microbiota, increasing the chances for obesity in adulthood, researchers from the University of Michigan School of Public Health have found.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."
› Verified 9 days ago
| Entity Name | Gulf Health Hospitals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134164924 PECOS PAC ID: 3375448491 Enrollment ID: O20110208000622 |
News Archive
Analysts, lobbyists and journalists are still examining the announcement that three large health insurance companies would allow some of the health law's more popular consumer provisions to go forward no matter how the court decides.
A new genetic analysis, published March 19th in the open-access journal PLoS Neglected Tropical Diseases, suggests that the parasitic worm Schistosoma mekongi is more widespread than previously thought.
Pain Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) resubmission for REMOXY (controlled-release oxycodone) and has classified it as a Class 2 resubmission.
Exposure to lead during early development can alter the the gut microbiota, increasing the chances for obesity in adulthood, researchers from the University of Michigan School of Public Health have found.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."
› Verified 9 days ago
| Entity Name | Blue Lake Health Springhill Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194496216 PECOS PAC ID: 2365830007 Enrollment ID: O20211028001840 |
News Archive
Analysts, lobbyists and journalists are still examining the announcement that three large health insurance companies would allow some of the health law's more popular consumer provisions to go forward no matter how the court decides.
A new genetic analysis, published March 19th in the open-access journal PLoS Neglected Tropical Diseases, suggests that the parasitic worm Schistosoma mekongi is more widespread than previously thought.
Pain Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) resubmission for REMOXY (controlled-release oxycodone) and has classified it as a Class 2 resubmission.
Exposure to lead during early development can alter the the gut microbiota, increasing the chances for obesity in adulthood, researchers from the University of Michigan School of Public Health have found.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Shotlander, 2101 Highway 90, Gautier, MS 39553-5340 Ph: () - | Robert Shotlander, 2809 Denny Ave, Pascagoula, MS 39581-5301 Ph: (228) 809-5000 |
News Archive
Analysts, lobbyists and journalists are still examining the announcement that three large health insurance companies would allow some of the health law's more popular consumer provisions to go forward no matter how the court decides.
A new genetic analysis, published March 19th in the open-access journal PLoS Neglected Tropical Diseases, suggests that the parasitic worm Schistosoma mekongi is more widespread than previously thought.
Pain Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) resubmission for REMOXY (controlled-release oxycodone) and has classified it as a Class 2 resubmission.
Exposure to lead during early development can alter the the gut microbiota, increasing the chances for obesity in adulthood, researchers from the University of Michigan School of Public Health have found.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."
› Verified 9 days ago
Amanda Graham Dobbins, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-806-4525 | |
Mr. Laird Miller, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5000 | |
Andrew J Zielinski, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5540 Fax: 228-809-1153 | |
Mr. Christopher Arlen Jones, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5531 Fax: 228-809-1153 | |
Jonathan White, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5000 | |
Mrs. Christine Cooper Bowman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2809 Denny Ave, Pascagoula, MS 39581 Phone: 228-809-5000 |